ClinicalTrials.gg
TerminatedNCT03085810Updated Jan 15, 2025Results posted

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

A Phase 3 interventional study of Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Hoffmann-La Roche. Terminated at 193 sites in 29 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,225
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
Largest of 10
1,225 · median 404
Started
2017
the only one that year
Phase 3
6 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
Hoffmann-La Roche

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one has the largest enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 4th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Have a definite diagnosis of RRMS, as per the revised McDonald 2010 criteria
  • Have a length of disease duration, from first documented clinical attack consistent with MS disease of less than or equal to (\</=) 3 years
  • Within the last 12 months one or more clinically reported relapse(s) or one or more signs of MRI activity
  • EDSS of 0.0 to 3.5 inclusive, at screening
  • An agreement to use an acceptable method for women of , during the treatment period and for at least 6 months or longer after the last dose of study drug

Exclusion Criteria:

  • Secondary progressive multiple sclerosis or history of primary progressive or progressive relapsing MS
  • Inability to complete an MRI
  • Known presence of other neurological disorders

Exclusions Related to General Health:

  • Pregnancy or lactation
  • Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
  • History or currently active primary or secondary immunodeficiency
  • Lack of peripheral venous access
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Significant or uncontrolled somatic disease or any other significant disease that may preclude participant from participating in the study
  • Congestive heart failure ( III or IV functional severity)
  • Known active bacterial, viral, fungal, mycobacterial infection or other infection, (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks prior to screening or oral antibiotics 2 weeks prior to screening
  • History of , major opportunistic infections, alcohol or drug abuse, recurrent or chronic infection, and/or coagulation disorders

Exclusions Related to Medications:

  • Received any prior approved disease modifying treatment (DMT) with a label for MS, for example, interferons, glatiramer acetate, natalizumab, alemtuzumab, daclizumab, fingolimod, teiflunomide and dimethylfumarate
  • Receipt of a or attenuated live vaccine within 6 weeks prior to the baseline visit
  • Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
  • Any previous treatment with immunosuppressants/ immunomodulators/ antineoplastic therapies (cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cladribine, mitoxantrone, laquinimod, total body irradiation, or bone marrow transplantation)
  • Treatment with DMT
  • Treatment with fampridine/dalfamipridine unless on stable dose for >/=30 days prior to screening

Exclusion related to Shorter Infusion Substudy:

  • Any previous serious IRRs experienced with ocrelizumab treatment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,225 participants (actual)

Study arms

  • Experimental
    Ocrelizumab

    Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.

    Drug: Ocrelizumab

  • Active comparator
    Substudy Group 1

    At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration

    Drug: Ocrelizumab

  • Experimental
    Substudy Group 2

    At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration

    Drug: Ocrelizumab

Interventions

  • Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.

06

What researchers measure

Primary outcomes

  1. Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)

    The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits for a minimum of 24 weeks/48 weeks.

    Time frame: Baseline up to 4 years

  2. Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSS

    CDI is defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

    Time frame: At Weeks 24 and 48 during Year 1

  3. Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSS

    The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.

    Time frame: Year 1 (Weeks 24 and 48)

  4. Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSS

    CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

    Time frame: At Weeks 48, 72 and 96 during Year 2

  5. Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSS

    The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.

    Time frame: Year 2 (Weeks 72 and 96)

  6. Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSS

    CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

    Time frame: At Weeks 144, 168 and 192 during Year 4

  7. Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSS

    The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.

    Time frame: Year 4 (Weeks 168 and 192)

  8. Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSS

    Time frame: Year 1 (Week 48)

  9. Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSS

    Time frame: Year 2 (Week 96)

  10. Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSS

    Time frame: Year 3

  11. Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSS

    Time frame: Year 4

  12. Mean Change From Baseline in EDSS Score at Week 24

    Time frame: From Baseline to Week 24

  13. Mean Change From Baseline in EDSS Score at Week 48

    Time frame: From Baseline to Week 48

  14. Mean Change From Baseline in EDSS Score at Week 72

    Time frame: From Baseline to Week 72

  15. Mean Change From Baseline in EDSS Score at Week 96

    Time frame: Baseline, Week 96

  16. Mean Change From Baseline in EDSS Score at Week 120

    Time frame: Baseline, Week 120

  17. Mean Change From Baseline in EDSS Score at Week 144

    Time frame: Baseline, Week 144

  18. Mean Change From Baseline in EDSS Score at Week 168

    Time frame: Baseline, Week 168

  19. Mean Change From Baseline in EDSS Score at Week 192

    Time frame: Baseline, Week 192

  20. Percentage of Participants Without Protocol-Defined Event of Disease Activity

    Protocol-defined event of disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8 (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan.

    Time frame: Baseline up to 4 years

  21. Percentage of Participants Without Relapse

    Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.

    Time frame: Baseline up to 4 years

  22. Annualized Relapse Rate

    Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment. The adjusted annualized relapse rate is reported which is: Adjusted by age at disease diagnosis, Baseline EDSS, Presence of T1 Gd-enhanced lesion at screening and Presence of relapses in the last year prior to enrollment. Log-transformed exposure time is included as an offset variable. The report contains data up to week 192 of the treatment period of each individual participant.

    Time frame: Baseline up to 4 years

  23. Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy

    Time frame: Week 24 through Week 144

Secondary outcomes

  1. Percentage of Participants Who Are Relapse Free

    Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.

    Time frame: Week 192

  2. Percentage of Participants With No Evidence of Protocol Defined Disease Activity

    Protocol-defined disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8. (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan. Event-free rate

    Time frame: Weeks 96, 144, 192

  3. Percentage of Participants Without Protocol-defined Event of Evidence of Progression (NEP)

    NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (CDP; 20 percent \[%\] increase from baseline in timed 25 Foot Walk Test \[T25FWT\]; 20% increase from baseline in timed 9 hole peg test \[9HPT\]). CDP will be assessed using EDSS.

    Time frame: Weeks 96, 192

  4. Percentage of Participants With no Evidence of Progression Sustained for At Least 24 Weeks and no Active Disease (NEPAD)

    NEPAD is defined as no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse and no enlarging or new T2 or T1 Gd-enhancing lesion. CDP will be assessed using EDSS. Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.

    Time frame: Weeks 96, 192

  5. Secondary: Change From Baseline in Multiple Sclerosis Functional Composite Score (MSFC) Total

    MSFC combines the following: Timed 25 Foot Walk Test \[T25FWT\] for leg function \&ambulation measured in seconds (sec). The longer it takes to walk, higher the score indicating deterioration; 9 Hole Peg Test \[9HPT\] for arm \& handf unction measured in sec. Higher score=more time taken to complete test indicating deterioration. Paced Auditory Serial Addition Test \[PASAT\] for cognitive function (score range: 0-60, higher score=better cognitive processing speed). MSFC composite={\[Average(1/9-HPT)-Baseline Mean(1/9-HPT)/Baseline Std Dev(1/9-HPT)\]+\[-(Average T25FWT-Baseline Mean T25FWT)/Baseline Std-Dev T25FWT\]+\[(PASAT-3-BaselineMean PASAT-3)/Baseline Std Dev PASAT-3\]}/ 3.0. MSFC is based on the concept that scores for these 3 dimensions are combined to create a single score to detect change over time in a group of MS patients. Higher composite score=better overall function. Lower score=worse overall function. Higher mean change in total MSFC score=functional improvement at cohort level.

    Time frame: Weeks 24, 48, 72, 96, 120, 144, 168, 192

  6. Change From Baseline in MSFC Composite Timed 25 Foot Walk Test (T25FW) Score.

    The change in the mean score of T25FW is reported below. The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. Higher times indicate worse performance and greater impairment. Subsequently, the lower the mean change in the score over time, the better performance.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192

  7. Change From Baseline in MSFC Composite 9 Hole Peg Test (9HPT) Score

    The mean change in 9 Hole Peg Test (9HPT)-score is reported. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. The number of seconds it takes to complete the test, the higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.

    Time frame: Weeks 24, 48, 72, 96, 120, 144, 168, 192

  8. Change From Baseline in MSFC Composite (Paced Auditory Serial Addition Test [PASAT]) Score

    Mean change in the Paced Auditory Serial Addition Test \[PASAT\] score is reported. PASAT measures cognitive function. A total of 60 single digit numbers are presented by an audiotape/CD-rom at a constant rate in every 3 seconds (PASAT-3). Participants are required to add each new number to the one immediately before it. Due to the relative complexity of this test, a practice trial with a set of 10 numbers should be performed before the original test. Participants are allowed up to 3 practice trials. Two sets of numbers (forms A \& B) are developed to be used alternatively in every visit to minimize memorizing. The number of correct answers is recorded. The PASAT score ranges from 0 to 60, with higher values representing a better outcome in cognitive processing speed. Subsequently, higher values in mean changes from baseline over the study time indicate improvement in cognitive function.

    Time frame: Weeks 24, 48, 72, 96, 120, 144, 168, 192

  9. Change From Baseline in Cognitive Performance as Measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) - Symbol Digits Modalities Test (SDMT)

    BICAMS is assessing cognitive processing speed and verbal and visual memory. SDMT assesses processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 second time span. The higher the results, the better processing speed/working memory.

    Time frame: Baseline, Weeks 48, 96, 144, 192

  10. Change From Baseline in Cognitive Performance as Measured by BICAMS -California Verbal Learning Test-II (CVLT-II)

    BICAMS assesses cognitive processing speed and verbal and visual memory. The CLVT-II is an assessment of verbal learning and memory which measures recall and recognition scores, encoding strategies, learning rates and error types. A list learning task with 16 words from 4 semantic categories are read over a series of 5 list presentations. Recall is assessed after learning and at a 20-minute delay. The maximum possible score is 80 and a minimum is 0. A higher score indicated better recall.

    Time frame: Baseline, Weeks 48, 96, 144, 192

  11. Change From Baseline in Cognitive Performance as Measured by BICAMS - Brief Visuospatial Memory Test-Revised (BVMT-R)

    BICAMS assesses cognitive processing speed and verbal and visual memory. BVMT-R assesses visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

    Time frame: Baseline, Weeks 48, 96, 144, 192

  12. Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI

    Number of Lesions are categorized as followed: 1, 2, 3, \>1, \>3

    Time frame: Weeks 24, 48, 96, 144, 192

  13. Total Number of New and/or Enlarging T2 Lesion as Detected by Brain MRI

    Number of Lesions are categorized as followed: 1, 2, 3, \>1

    Time frame: Baseline, Weeks 24, 48, 96, 144, 192

  14. Change From Baseline in Total T1 Hypointense Lesion Volume as Detected by Brain MRI

    Time frame: Baseline, Weeks 48, 96, 144, 192

  15. Total Number of Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI

    Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI was measured for its volumes.

    Time frame: Baseline, Weeks 8, 24, 48, 96, 144, 192

  16. Change From Baseline in Brain Volume as Detected by Brain MRI

    Percentage change from Normalized brain volume in cm3 (cubic centimeter)values are reported

    Time frame: From Baseline to Weeks 24, 48, 96, 144, 192

  17. Percentage of Participants Without Treatment Discontinuation

    Time frame: Baseline up to 4 years

  18. Employment Status: Work Productivity and Activity Impairment Questionnaire (WAPI) Score

    WPAI scale measures impact of health problems on work productivity and regular activities: Absenteeism (Work Time Missed) measuring % of work time missed due to health issues; Presenteeism:Calculated as the percentage of impairment while working due to health problems. Overall Work Impairment:Calculated by combining absenteeism and presenteeism using the formula:Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism This formula accounts for both the time missed and the reduced productivity while at work. Activity Impairment: Calculated as the percentage of impairment in regular activities outside of work. Range: Each component is scored as 0%-100%). Higher % indicate greater impairment and worse outcomes.

    Time frame: Baseline, Weeks 24, 48, 96, 120, 144, 192

  19. SymptoMScreen Composite Score

    The SMSS consists of 12 items which are assessed on a seven-point Likert scale that ranges from 0 (not at all affected) to 6 (total limitation) \[7\]. The total score ranges from 0 to 72, with higher scores indicating more severe symptom endorsement.

    Time frame: Baseline, Weeks 24, 48, 96, 144, 192

  20. Quality of Life: Multiple Sclerosis Impact Scale (MSIS)-29 Questionnaire Score

    The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a questionnaire to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient's perspective, which includes 29 items self-reported measures associated with a physical scale and 9 items with a psychological scale. MSIS-29 scales are generated by summing items and it's ranging from 29-145'. The higher total MSIS-29 scores indicate a greater degree of disability. The mean change in MSIS-29 scores from baseline is reported. The decreasing values in the mean change from baseline indicate functional improvement from patients' perspective

    Time frame: Baseline, Weeks 24, 48, 96, 144, 192

  21. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 4 years

  22. Substudy: Number of Participants With IRR Overall and by Dose at Randomization

    Time frame: From Week 24 to Week 144

  23. Substudy: Severity of IRRs

    The number of participants with IRRs by most extreme intensity were reported (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 =life-threatening, grade 5 = fatal). Multiple IRRs in one participant are counted only once at the most extreme (highest) intensity observed.

    Time frame: From Week 24 to Week 144

  24. Substudy: Number of IRR Symptoms

    Time frame: From Week 24 to Week 144

  25. Substudy: IRRs Leading to Treatment Discontinuation

    Time frame: From Week 24 to Week 144

07

Results

Posted Jan 15, 2025

Participant flow

A prospective, multicenter, open-label, single-arm effectiveness and safety study enrolled 1225 eligible treatment-naive patients with early stage RMSR. The study consisted of screening period up 4 weeks and open-label treatment with ocrelizumab period up to 192 week.

Main Study
Participant flow — Main Study
MilestoneMain Study - OcrelizumabSubstudy - Conventional InfusionSubstudy - Shorter Infusion
Started122500
Completed101000
Not completed21500
Withdrew: Withdrawal by subject7700
Withdrew: Terminated by sponsor1400
Withdrew: Protocol violation1500
Withdrew: Physician decision1300
Withdrew: Lost to follow-up1700
Withdrew: Adverse event2500
Withdrew: Pregnancy700
Withdrew: Changed to commercial ocrelizumab400
Withdrew: Lack of efficacy1000
Withdrew: Death1200
Withdrew: Disease progression100
Withdrew: Site closure300
Withdrew: Planned pregnancy1700
Substudy (Week 24 to Week 144)
Participant flow — Substudy (Week 24 to Week 144)
MilestoneMain Study - OcrelizumabSubstudy - Conventional InfusionSubstudy - Shorter Infusion
Started0373372
Completed002
Not completed0373370
Withdrew: Withdrawal due to infusion related reaction (irr)003
Withdrew: Withdrawal by subject057
Withdrew: Substudy stopped by sponsor0355352
Withdrew: Reason not specified0138

Outcome measures

PrimaryTime to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)

The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits for a minimum of 24 weeks/48 weeks.

Time frame:
Baseline up to 4 years
Reported as:
Median · weeks
Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)
weeksOcrelizumab
CPD Sustained for at Least 24 weeksNA (NA to NA)
CDP Sustained for at Least 48 weeksNA (NA to NA)
PrimaryPercentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSS

CDI is defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

Time frame:
At Weeks 24 and 48 during Year 1
Reported as:
Number · Percentage of Participants
Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSS
Percentage of ParticipantsOcrelizumab
CDI Sustained for 24 weeks: At Week 2495.11 (92.03 to 97.03)
CDI Sustained for 24 weeks: At Week 4883.50 (78.81 to 87.24)
CDI Sustained for 48 weeks: At Week 4887.54 (83.28 to 90.77)
PrimaryPercentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSS

The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.

Time frame:
Year 1 (Weeks 24 and 48)
Reported as:
Number · Percentage of Participants
Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSS
Percentage of ParticipantsOcrelizumab
CDP Sustained for 24 weeks: At Week 2499.55 (98.62 to 99.86)
CDP Sustained for 24 weeks: At Week 4897.30 (95.75 to 98.29)
CDP Sustained for 48 weeks: At Week 4898.05 (96.67 to 98.87)
PrimaryPercentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSS

CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24/48 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

Time frame:
At Weeks 48, 72 and 96 during Year 2
Reported as:
Number · Percentage of Participants
Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSS
Percentage of ParticipantsOcrelizumab
CDI Sustained for 24 weeks: At Week 48100.0 (100.00 to 100.00)
CDI Sustained for 48 weeks: At Week 48100.00 (100.00 to 100.00)
CDI Sustained for 24 weeks: At Week 72:97.20 (94.22 to 98.66)
CDI Sustained for 48 weeks: At Week 7297.60 (94.74 to 98.91)
CDI Sustained for 24 weeks: At Week 9690.29 (85.71 to 93.46)
CDI Sustained for 48 weeks: At Week 9692.55 (88.41 to 92.55)
PrimaryPercentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSS

The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.

Time frame:
Year 2 (Weeks 72 and 96)
Reported as:
Number · Percentage of Particiopants
Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSS
Percentage of ParticiopantsOcrelizumab
CDP Sustained for 24 weeks: At Week 7293.97 (91.87 to 95.54)
CDP Sustained for 48 weeks: At Week 7295.18 (93.25 to 96.56)
CDP Sustained for 24 weeks: Week 9691.65 (89.26 to 93.52)
CDP Sustained for 48 weeks: Week 9693.47 (91.30 to 95.12)
PrimaryPercentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSS

CDI is defined as an improvement of 1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological worsening (measured only participants with a baseline EDSS of ≥2.0). EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

Time frame:
At Weeks 144, 168 and 192 during Year 4
Reported as:
Number · Percentage of Participants
Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSS
Percentage of ParticipantsOcrelizumab
CDI Sustained for 24 weeks: At Week 144100.00 (100.00 to 100.00)
CDI Sustained for 48 weeks: At Week 144100.00 (100.00 to 100.00)
CDI Sustained for 24 weeks: At Week 16899.54 (96.77 to 99.93)
CDI Sustained for 48 weeks: At Week 168100.00 (100.00 to 100.00)
CDI Sustained for 24 weeks: At Week 19293.77 (89.51 to 96.34)
CDI Sustained for 48 weeks: At Week 19298.01 (94.77 to 99.25)
PrimaryPercentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSS

The EDSS-Expanded Disability Status Scale is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Disability progression as measured by EDSS is defined as ≥1 point increase in EDSS score from a baseline EDSS score of 1-5 inclusive, a 0.5-increase from a baseline EDSS score higher than 5 and a 1.5-increase from a baseline EDSS score from 0 to 1 exclusive. Disability progression was considered confirmed if a sustained change in EDSS for a minimum of 24 weeks (-2 weeks) from the initial progression event was seen i.e. the change in EDSS must have been sustained at all available visits (during Year 1) for a minimum of 24 weeks/48 weeks. Percentage of participants who did not have CPD sustained for 24 and 48 weeks are reported here.

Time frame:
Year 4 (Weeks 168 and 192)
Reported as:
Number · Percentage of Participants
Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSS
Percentage of ParticipantsOcrelizumab
CDP Sustained for 24 weeks: At Week 16885.98 (83.04 to 88.44)
CDP Sustained for 48 weeks: At Week 16887.98 (85.20 to 90.27)
CDP Sustained for 24 weeks: At Week 19284.18 (81.08 to 86.81)
CDP Sustained for 48 weeks: At Week 19286.48 (83.54 to 88.93)
PrimaryPercentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSS
Time frame:
Year 1 (Week 48)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSS
Percentage of ParticipantsOcrelizumab
Week 48 Worsened (>0.5)9.3
Week 48 Stable (Change <= 0.5 and >= -0.5)73.3
Week 48 Improved (<-0.5)17.5
PrimaryPercentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSS
Time frame:
Year 2 (Week 96)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSS
Percentage of ParticipantsOcrelizumab
Week 96 Worsened (>0.5)11.9
Week 96 Stable (Change <= 0.5 and >= -0.5)76.6
Week 96 Improved (<-0.5)11.6
PrimaryPercentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSS
Time frame:
Year 3
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSS
Percentage of ParticipantsOcrelizumab
Worsened (>0.5)9.3
Stable (Change <= 0.5 and >= -0.5)81.5
Improved (<-0.5)9.2
PrimaryPercentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSS
Time frame:
Year 4
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSS
Percentage of ParticipantsOcrelizumab
Worsened (>0.5)18.0
Stable (Change <= 0.5 and >= -0.5)59.3
Improved (<-0.5)22.8
PrimaryMean Change From Baseline in EDSS Score at Week 24
Time frame:
From Baseline to Week 24
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 24
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 24-0.14 ± 0.68
PrimaryMean Change From Baseline in EDSS Score at Week 48
Time frame:
From Baseline to Week 48
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 48
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 48-0.14 ± 0.77
PrimaryMean Change From Baseline in EDSS Score at Week 72
Time frame:
From Baseline to Week 72
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 72
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 72-0.09 ± 0.89
PrimaryMean Change From Baseline in EDSS Score at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 96
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 96-0.12 ± 0.95
PrimaryMean Change From Baseline in EDSS Score at Week 120
Time frame:
Baseline, Week 120
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 120
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 120-0.10 ± 0.94
PrimaryMean Change From Baseline in EDSS Score at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 144
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 144-0.10 ± 1.00
PrimaryMean Change From Baseline in EDSS Score at Week 168
Time frame:
Baseline, Week 168
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 168
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 168-0.05 ± 1.05
PrimaryMean Change From Baseline in EDSS Score at Week 192
Time frame:
Baseline, Week 192
Reported as:
Mean · Change in Total EDSS Score
Mean Change From Baseline in EDSS Score at Week 192
Change in Total EDSS ScoreOcrelizumab
Mean Change From Baseline in EDSS Score at Week 192-0.06 ± 1.06
PrimaryPercentage of Participants Without Protocol-Defined Event of Disease Activity

Protocol-defined event of disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8 (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan.

Time frame:
Baseline up to 4 years
Reported as:
Number · Percentage of participants
Percentage of Participants Without Protocol-Defined Event of Disease Activity
Percentage of participantsOcrelizumab
Week 2495.98 (94.20 to 97.23)
Week 4888.94 (86.30 to 91.09)
Week 7283.94 (80.92 to 86.52)
Week 9680.38 (77.14 to 83.21)
Week 12077.38 (73.99 to 80.39)
Week 14475.76 (72.28 to 78.86)
Week 16872.79 (69.18 to 76.05)
Week 19270.67 (66.97 to 74.04)
PrimaryPercentage of Participants Without Relapse

Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.

Time frame:
Baseline up to 4 years
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Relapse
Percentage of ParticipantsOcrelizumab
Week 2498.52 (97.26 to 99.20)
Week 4897.91 (96.50 to 98.76)
Week 7296.25 (94.49 to 97.45)
Week 9695.32 (93.41 to 96.69)
Week 12093.90 (91.78 to 95.49)
Week 14493.09 (90.85 to 94.79)
Week 16892.43 (90.10 to 94.23)
Week 19291.56 (89.12 to 93.48)
PrimaryAnnualized Relapse Rate

Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment. The adjusted annualized relapse rate is reported which is: Adjusted by age at disease diagnosis, Baseline EDSS, Presence of T1 Gd-enhanced lesion at screening and Presence of relapses in the last year prior to enrollment. Log-transformed exposure time is included as an offset variable. The report contains data up to week 192 of the treatment period of each individual participant.

Time frame:
Baseline up to 4 years
Reported as:
Number · events per participant per year
Annualized Relapse Rate
events per participant per yearOcrelizumab
Annualized Relapse Rate0.02 (0.015 to 0.027)
PrimarySub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy
Time frame:
Week 24 through Week 144
Reported as:
Count of participants · Participants
Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy
ParticipantsSubstudy - Conventional InfusionSubstudy - Shorter Infusion
Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy101107
SecondaryPercentage of Participants Who Are Relapse Free

Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.

Time frame:
Week 192
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Are Relapse Free
Percentage of ParticipantsOcrelizumab
Percentage of Participants Who Are Relapse Free92.00 (89.7 to 94.0)
SecondaryPercentage of Participants With No Evidence of Protocol Defined Disease Activity

Protocol-defined disease activity is defined as having at least one of the following: (1). protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis \[MS\], as determined using EDSS/Functional Systems Score \[FSS\] assessment). (2). CDP, as determined using EDSS. (3). a T1 Gd-enhanced lesion after Week 8. (4). a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI) after Week 8 compared to the Week 8 MRI scan. Event-free rate

Time frame:
Weeks 96, 144, 192
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Evidence of Protocol Defined Disease Activity
Percentage of ParticipantsOcrelizumab
Week 9680.38 (77.14 to 83.21)
Week 14475.76 (72.28 to 78.86)
Week 19270.67 (66.97 to 74.04)
SecondaryPercentage of Participants Without Protocol-defined Event of Evidence of Progression (NEP)

NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (CDP; 20 percent \[%\] increase from baseline in timed 25 Foot Walk Test \[T25FWT\]; 20% increase from baseline in timed 9 hole peg test \[9HPT\]). CDP will be assessed using EDSS.

Time frame:
Weeks 96, 192
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Protocol-defined Event of Evidence of Progression (NEP)
Percentage of ParticipantsOcrelizumab
Week 9679.60 (76.33 to 82.48)
Week 19269.16 (65.40 to 72.60)
SecondaryPercentage of Participants With no Evidence of Progression Sustained for At Least 24 Weeks and no Active Disease (NEPAD)

NEPAD is defined as no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse and no enlarging or new T2 or T1 Gd-enhancing lesion. CDP will be assessed using EDSS. Relapse is defined as occurrence of new or worsening neurological symptoms attributable to MS, as determined using EDSS/FSS assessment.

Time frame:
Weeks 96, 192
Reported as:
Number · Percentage of Participants
Percentage of Participants With no Evidence of Progression Sustained for At Least 24 Weeks and no Active Disease (NEPAD)
Percentage of ParticipantsOcrelizumab
Week 9670.29 (66.65 to 73.62)
Week 19258.89 (54.96 to 62.60)
SecondarySecondary: Change From Baseline in Multiple Sclerosis Functional Composite Score (MSFC) Total

MSFC combines the following: Timed 25 Foot Walk Test \[T25FWT\] for leg function \&ambulation measured in seconds (sec). The longer it takes to walk, higher the score indicating deterioration; 9 Hole Peg Test \[9HPT\] for arm \& handf unction measured in sec. Higher score=more time taken to complete test indicating deterioration. Paced Auditory Serial Addition Test \[PASAT\] for cognitive function (score range: 0-60, higher score=better cognitive processing speed). MSFC composite={\[Average(1/9-HPT)-Baseline Mean(1/9-HPT)/Baseline Std Dev(1/9-HPT)\]+\[-(Average T25FWT-Baseline Mean T25FWT)/Baseline Std-Dev T25FWT\]+\[(PASAT-3-BaselineMean PASAT-3)/Baseline Std Dev PASAT-3\]}/ 3.0. MSFC is based on the concept that scores for these 3 dimensions are combined to create a single score to detect change over time in a group of MS patients. Higher composite score=better overall function. Lower score=worse overall function. Higher mean change in total MSFC score=functional improvement at cohort level.

Time frame:
Weeks 24, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · score on a scale
Secondary: Change From Baseline in Multiple Sclerosis Functional Composite Score (MSFC) Total
score on a scaleOcrelizumab
Change at Week 240.09 ± 0.67
Change at Week 480.11 ± 0.54
Change at Week 720.12 ± 0.45
Change at Week 960.14 ± 0.53
Change at Week 1200.16 ± 0.61
Change at Week 1440.16 ± 0.48
Change at Week 1680.18 ± 0.56
Change at Week 1920.19 ± 0.72
SecondaryChange From Baseline in MSFC Composite Timed 25 Foot Walk Test (T25FW) Score.

The change in the mean score of T25FW is reported below. The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. Higher times indicate worse performance and greater impairment. Subsequently, the lower the mean change in the score over time, the better performance.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · seconds
Change From Baseline in MSFC Composite Timed 25 Foot Walk Test (T25FW) Score.
secondsOcrelizumab
Change at Week 24-0.31 ± 6.62
Change at Week 48-0.49 ± 6.88
Change at Week 72-0.56 ± 6.99
Change at Week 96-0.62 ± 6.95
Change at Week 120-0.44 ± 7.94
Change at Week 144-0.97 ± 6.25
Change at Week 168-0.83 ± 6.64
Change at Week 1920.09 ± 9.37
SecondaryChange From Baseline in MSFC Composite 9 Hole Peg Test (9HPT) Score

The mean change in 9 Hole Peg Test (9HPT)-score is reported. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. The number of seconds it takes to complete the test, the higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.

Time frame:
Weeks 24, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · seconds
Change From Baseline in MSFC Composite 9 Hole Peg Test (9HPT) Score
secondsOcrelizumab
Change at Week 24-0.47 ± 14.44
Change at Week 48-1.22 ± 11.54
Change at Week 72-1.78 ± 8.09
Change at Week 96-1.67 ± 10.91
Change at Week 120-0.87 ± 15.21
Change at Week 144-1.91 ± 8.70
Change at Week 168-1.84 ± 10.68
Change at Week 192-0.73 ± 17.55
SecondaryChange From Baseline in MSFC Composite (Paced Auditory Serial Addition Test [PASAT]) Score

Mean change in the Paced Auditory Serial Addition Test \[PASAT\] score is reported. PASAT measures cognitive function. A total of 60 single digit numbers are presented by an audiotape/CD-rom at a constant rate in every 3 seconds (PASAT-3). Participants are required to add each new number to the one immediately before it. Due to the relative complexity of this test, a practice trial with a set of 10 numbers should be performed before the original test. Participants are allowed up to 3 practice trials. Two sets of numbers (forms A \& B) are developed to be used alternatively in every visit to minimize memorizing. The number of correct answers is recorded. The PASAT score ranges from 0 to 60, with higher values representing a better outcome in cognitive processing speed. Subsequently, higher values in mean changes from baseline over the study time indicate improvement in cognitive function.

Time frame:
Weeks 24, 48, 72, 96, 120, 144, 168, 192
Reported as:
Mean · score on a scale
Change From Baseline in MSFC Composite (Paced Auditory Serial Addition Test [PASAT]) Score
score on a scaleOcrelizumab
Change at Week 244.18 ± 9.26
Change at Week 485.40 ± 9.52
Change at Week 726.33 ± 11.59
Change at Week 967.66 ± 10.93
Change at Week 1207.69 ± 12.95
Change at Week 1448.45 ± 10.02
Change at Week 1688.47 ± 11.79
Change at Week 1929.64 ± 11.56
SecondaryChange From Baseline in Cognitive Performance as Measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) - Symbol Digits Modalities Test (SDMT)

BICAMS is assessing cognitive processing speed and verbal and visual memory. SDMT assesses processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 second time span. The higher the results, the better processing speed/working memory.

Time frame:
Baseline, Weeks 48, 96, 144, 192
Reported as:
Mean · responses over 90 seconds
Change From Baseline in Cognitive Performance as Measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) - Symbol Digits Modalities Test (SDMT)
responses over 90 secondsOcrelizumab
Change at Week 482.48 ± 10.12
Change at Week 961.89 ± 9.98
Change at Week 1443.33 ± 9.31
Change at Week 1924.38 ± 10.38
SecondaryChange From Baseline in Cognitive Performance as Measured by BICAMS -California Verbal Learning Test-II (CVLT-II)

BICAMS assesses cognitive processing speed and verbal and visual memory. The CLVT-II is an assessment of verbal learning and memory which measures recall and recognition scores, encoding strategies, learning rates and error types. A list learning task with 16 words from 4 semantic categories are read over a series of 5 list presentations. Recall is assessed after learning and at a 20-minute delay. The maximum possible score is 80 and a minimum is 0. A higher score indicated better recall.

Time frame:
Baseline, Weeks 48, 96, 144, 192
Reported as:
Mean · score on a scale
Change From Baseline in Cognitive Performance as Measured by BICAMS -California Verbal Learning Test-II (CVLT-II)
score on a scaleOcrelizumab
Change at Week 482.02 ± 8.29
Change at Week 962.71 ± 9.25
Change at Week 1443.99 ± 7.60
Change at Week 1924.28 ± 13.76
SecondaryChange From Baseline in Cognitive Performance as Measured by BICAMS - Brief Visuospatial Memory Test-Revised (BVMT-R)

BICAMS assesses cognitive processing speed and verbal and visual memory. BVMT-R assesses visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

Time frame:
Baseline, Weeks 48, 96, 144, 192
Reported as:
Mean · points on a scale
Change From Baseline in Cognitive Performance as Measured by BICAMS - Brief Visuospatial Memory Test-Revised (BVMT-R)
points on a scaleOcrelizumab
Baseline23.69 ± 6.44
Change at Week 48-0.71 ± 5.31
Change at Week 960.82 ± 5.68
Change at Week 1443.15 ± 5.37
Change at Week 1921.06 ± 7.09
SecondaryTotal Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI

Number of Lesions are categorized as followed: 1, 2, 3, \>1, \>3

Time frame:
Weeks 24, 48, 96, 144, 192
Reported as:
Number · Number of Lesions
Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI
Number of LesionsOcrelizumab
Week 24 Number of Lesions 0659
Week 24 Number of Lesions 16
Week 24 Number of Lesions 22
Week 24 Number of Lesions >12
Week 48 Number of Lesions 0650
Week 48 Number of Lesions 17
Week 96 Number of Lesions 0629
Week 96 Number of Lesions 11
Week 144 Number of Lesions 0567
Week 144 Number of Lesions 11
Week 144 Number of Lesions 31
Week 144 Number of Lesions >11
Week 192 Number of Lesions 0545
Week 192 Number of Lesions 11
SecondaryTotal Number of New and/or Enlarging T2 Lesion as Detected by Brain MRI

Number of Lesions are categorized as followed: 1, 2, 3, \>1

Time frame:
Baseline, Weeks 24, 48, 96, 144, 192
Reported as:
Number · Number of Lesions
Total Number of New and/or Enlarging T2 Lesion as Detected by Brain MRI
Number of LesionsOcrelizumab
Week 24 Number of Lesions 0651
Week 24 Number of Lesions 113
Week 24 Number of Lesions 23
Week 24 Number of Lesions >13
Week 48 Number of Lesions 0644
Week 48 Number of Lesions 111
Week 48 Number of Lesions 23
Week 48 Number of Lesions 32
Week 48 Number of Lesions >15
Week 96 Number of Lesions 0624
Week 96 Number of Lesions 18
Week 96 Number of Lesions 21
Week 96 Number of Lesions >11
Week 144 Number of Lesions 0564
Week 144 Number of Lesions 16
Week 144 Number of Lesions 21
Week 144 Number of Lesions 31
Week 144 Number of Lesions >12
Week 192 Number of Lesions 0546
Week 192 Number of Lesions 14
Week 192 Number of Lesions 21
Week 192 Number of Lesions >11
SecondaryChange From Baseline in Total T1 Hypointense Lesion Volume as Detected by Brain MRI
Time frame:
Baseline, Weeks 48, 96, 144, 192
Reported as:
Mean · Micro Liter
Change From Baseline in Total T1 Hypointense Lesion Volume as Detected by Brain MRI
Micro LiterOcrelizumab
Week 48-310.63 ± 708.07
Week 96-405.61 ± 755.99
Week 144-359.76 ± 761.84
Week 192-307.64 ± 797.87
SecondaryTotal Number of Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI

Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI was measured for its volumes.

Time frame:
Baseline, Weeks 8, 24, 48, 96, 144, 192
Reported as:
Number · Number of Lesions
Total Number of Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI
Number of LesionsOcrelizumab
Baseline Week 8 0633
Baseline Week 8 16
Week 24 0635
Week 24 16
Week 48 0631
Week 48 16
Week 96 0611
Week 96 17
Week 144 0550
Week 144 15
Week 192 0530
Week 192 15
SecondaryChange From Baseline in Brain Volume as Detected by Brain MRI

Percentage change from Normalized brain volume in cm3 (cubic centimeter)values are reported

Time frame:
From Baseline to Weeks 24, 48, 96, 144, 192
Reported as:
Mean · Percentage Change in Volume (cm3)
Change From Baseline in Brain Volume as Detected by Brain MRI
Percentage Change in Volume (cm3)Ocrelizumab
Week 24-0.189 ± 0.564
Week 48-0.479 ± 0.733
Week 96-0.909 ± 0.930
Week 144-1.283 ± 1.156
Week 192-1.535 ± 1.311
SecondaryPercentage of Participants Without Treatment Discontinuation
Time frame:
Baseline up to 4 years
Reported as:
Number · Percentage %
Percentage of Participants Without Treatment Discontinuation
Percentage %Ocrelizumab
Week 2498.97 (97.85 to 99.51)
Week 4897.49 (96.00 to 98.45)
Week 7296.02 (94.25 to 97.25)
Week 9693.51 (91.38 to 95.13)
Week 12092.04 (89.73 to 93.84)
Week 14489.23 (86.65 to 91.34)
Week 16887.17 (84.41 to 89.47)
Week 19283.85 (80.85 to 86.42)
SecondaryEmployment Status: Work Productivity and Activity Impairment Questionnaire (WAPI) Score

WPAI scale measures impact of health problems on work productivity and regular activities: Absenteeism (Work Time Missed) measuring % of work time missed due to health issues; Presenteeism:Calculated as the percentage of impairment while working due to health problems. Overall Work Impairment:Calculated by combining absenteeism and presenteeism using the formula:Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism Overall Work Impairment=Absenteeism+(1-Absenteeism)×Presenteeism This formula accounts for both the time missed and the reduced productivity while at work. Activity Impairment: Calculated as the percentage of impairment in regular activities outside of work. Range: Each component is scored as 0%-100%). Higher % indicate greater impairment and worse outcomes.

Time frame:
Baseline, Weeks 24, 48, 96, 120, 144, 192
Reported as:
Mean · WAPI Sub-Score
Employment Status: Work Productivity and Activity Impairment Questionnaire (WAPI) Score
WAPI Sub-ScoreOcrelizumab
Work productivity Baseline26.33 ± 31.84
Work productivity Week 2417.65 ± 25.04
Work productivity Week 4818.83 ± 25.92
Work productivity Week 9616.46 ± 23.10
Work productivity Week 14416.78 ± 23.85
Work productivity Week 19215.80 ± 22.25
Activity Impairment Baseline23.23 ± 24.79
Activity Impairment Week 2418.09 ± 22.15
Presenteeism Week 4818.85 ± 23.37
Activity Impairment Week 9617.79 ± 22.92
Activity Impairment Week 14417.80 ± 23.74
Activity Impairment Week 19218.18 ± 23.25
SecondarySymptoMScreen Composite Score

The SMSS consists of 12 items which are assessed on a seven-point Likert scale that ranges from 0 (not at all affected) to 6 (total limitation) \[7\]. The total score ranges from 0 to 72, with higher scores indicating more severe symptom endorsement.

Time frame:
Baseline, Weeks 24, 48, 96, 144, 192
Reported as:
Mean · Change in SymptoMScreen Composite Score
SymptoMScreen Composite Score
Change in SymptoMScreen Composite ScoreOcrelizumab
Week 24-0.1 ± 0.9
Week 48-0.1 ± 1.0
Week 960.0 ± 1.1
Week 1440.0 ± 1.1
Week 1920.0 ± 1.1
SecondaryQuality of Life: Multiple Sclerosis Impact Scale (MSIS)-29 Questionnaire Score

The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a questionnaire to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient's perspective, which includes 29 items self-reported measures associated with a physical scale and 9 items with a psychological scale. MSIS-29 scales are generated by summing items and it's ranging from 29-145'. The higher total MSIS-29 scores indicate a greater degree of disability. The mean change in MSIS-29 scores from baseline is reported. The decreasing values in the mean change from baseline indicate functional improvement from patients' perspective

Time frame:
Baseline, Weeks 24, 48, 96, 144, 192
Reported as:
Mean · Change in MSIS-29 Mean Score
Quality of Life: Multiple Sclerosis Impact Scale (MSIS)-29 Questionnaire Score
Change in MSIS-29 Mean ScoreOcrelizumab
Week 24-2.43 ± 12.13
Week 48-2.15 ± 13.04
Week 96-1.26 ± 14.31
Week 144-0.73 ± 14.83
Week 192-0.63 ± 16.04
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to 4 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of ParticipantsOcrelizumab
Adverse Events95.8
Serious Adverse Events15.0
SecondarySubstudy: Number of Participants With IRR Overall and by Dose at Randomization
Time frame:
From Week 24 to Week 144
Reported as:
Count of participants · Participants
Substudy: Number of Participants With IRR Overall and by Dose at Randomization
ParticipantsSubstudy - Conventional InfusionSubstudy - Shorter Infusion
All Randomized Doses (Overall)155172
1st Randomized Dose101107
2nd Randomized Dose8496
3rd Randomized Dose6282
4th Randomized Dose1417
5th Randomized Dose13
6th Randomized Dose00
SecondarySubstudy: Severity of IRRs

The number of participants with IRRs by most extreme intensity were reported (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 =life-threatening, grade 5 = fatal). Multiple IRRs in one participant are counted only once at the most extreme (highest) intensity observed.

Time frame:
From Week 24 to Week 144
Reported as:
Count of participants · Participants
Substudy: Severity of IRRs
ParticipantsSubstudy - Conventional InfusionSubstudy - Shorter Infusion
Grade 1 (Mild)8892
Grade 2 (Moderate)6676
Grade 3 (Severe)14
Grade 4 (Life-Threatening)00
Grade 5 (Fatal)00
SecondarySubstudy: Number of IRR Symptoms
Time frame:
From Week 24 to Week 144
Reported as:
Number · symptoms
Substudy: Number of IRR Symptoms
symptomsSubstudy - Conventional InfusionSubstudy - Shorter Infusion
Substudy: Number of IRR Symptoms471458
SecondarySubstudy: IRRs Leading to Treatment Discontinuation
Time frame:
From Week 24 to Week 144
Reported as:
Number · symptoms
Substudy: IRRs Leading to Treatment Discontinuation
symptomsSubstudy - Conventional InfusionSubstudy - Shorter Infusion
Substudy: IRRs Leading to Treatment Discontinuation00

Adverse events

Collected over Main study: Up to 4 Years Sub-study: Week 24 to Week 144. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab13/1,225 (1.1%)184/1,225 (15%)1,110/1,225 (90.6%)
Substudy - Conventional Infusion2/370 (0.5%)21/370 (5.7%)251/370 (67.8%)
Substudy - Shorter Infusion1/375 (0.3%)19/375 (5.1%)276/375 (73.6%)
Most frequent serious events
Showing 10 of 129
Most frequent serious events
EventOcrelizumabSubstudy - Conventional InfusionSubstudy - Shorter Infusion
COVID-19Infections and infestations23/12252/3701/375
COVID-19 PNEUMONIAInfections and infestations17/12250/3702/375
MULTIPLE SCLEROSIS RELAPSENervous system disorders9/12250/3700/375
PNEUMONIAInfections and infestations8/12250/3701/375
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions7/12251/3700/375
URINARY TRACT INFECTIONInfections and infestations5/12250/3702/375
INFUSION RELATED REACTIONInjury, poisoning and procedural complications6/12250/3701/375
APPENDICITISInfections and infestations5/12250/3701/375
PYELONEPHRITISInfections and infestations4/12250/3700/375
ABORTION INDUCEDSurgical and medical procedures4/12250/3700/375
Most frequent other events
Showing 10 of 28
Most frequent other events
EventOcrelizumabSubstudy - Conventional InfusionSubstudy - Shorter Infusion
INFUSION RELATED REACTIONInjury, poisoning and procedural complications674/1225154/370172/375
NASOPHARYNGITISInfections and infestations320/122558/37050/375
HEADACHENervous system disorders295/122546/37037/375
COVID-19Infections and infestations291/122514/37013/375
FATIGUEGeneral disorders201/122528/37028/375
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations196/122528/37035/375
URINARY TRACT INFECTIONInfections and infestations184/122520/37024/375
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders133/122518/37014/375
ARTHRALGIAMusculoskeletal and connective tissue disorders132/122517/37015/375
COUGHRespiratory, thoracic and mediastinal disorders126/122513/37018/375

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ocrelizumab
Mean32.7 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab
Female784
Male441
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ocrelizumab
Hispanic or Latino145
Not Hispanic or Latino960
Unknown or Not Reported120
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab
American Indian or Alaska Native11
Asian19
Native Hawaiian or Other Pacific Islander2
Black or African American34
White1007
More than one race37
Unknown or Not Reported115
08

Study locations

193 sites
  • University of California Irvine
    Irvine, California 92697, United States
  • Palo Alto Medical Foundation Research Center
    Sunnyvale, California 94086, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Advanced Neurology of Colorado, LLC
    Fort Collins, Colorado 80528, United States
  • KI Health Partners, LLC; New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • University of South Florida - Bradenton
    Tampa, Florida 33612, United States
  • Shepherd Center Inc.
    Atlanta, Georgia 30309, United States
  • College Park Family Care Ctr
    Overland Park, Kansas 66212, United States
  • The NeuroMedical Center
    Baton Rouge, Louisiana 70810, United States
  • Maine Medical Center
    Scarborough, Maine 04074, United States
  • University of Maryland Medical Center; Department of Neurology
    Baltimore, Maryland 21201, United States
  • Neurology Center of New England
    Foxboro, Massachusetts 02035, United States
  • Dragonfly Research, LLC
    Wellesley, Massachusetts 02481, United States
  • Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • Cleveland Clinic Lou Ruvo; Center for Brain Research
    Las Vegas, Nevada 89106, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Island Neurological Associates, P.C.
    Plainview, New York 11803, United States
  • Neurology Associates PA
    Hickory, North Carolina 28602, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40
    Cleveland, Ohio 44195, United States
  • Neurology Specialists, Inc
    Dayton, Ohio 45417, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Kane Hall Barry Neurology
    Bedford, Texas 76021, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
    Milwaukee, Wisconsin 53215, United States
  • Centro de Especialidades Neurológicas y Rehabilitación - CENyR
    Buenos Aires, C1424, Argentina
  • Hospital Churruca Visca
    Buenos Aires, C1437JCP, Argentina
  • Fundacion Rosarina de Neurorehabilitacion
    Rosario, S2000BZL, Argentina
  • Brain and Mind Centre
    Camperdown, New South Wales 2050, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • John Hunter Hospital
    New Lambton, New South Wales 2305, Australia
  • Royal North Shore Hospital; Department of Neurology
    St Leonards, New South Wales 2065, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Box Hill Hospital; Department of Neurology
    Box Hill, Victoria 3128, Australia
  • Austin Hospital; Department of Neurology
    Heidelberg, Victoria 3084, Australia
  • Royal Melbourne Hospital; Department of Neurology
    Parkville, Victoria 3050, Australia
  • Perron Institute for Neurological and Translational Science
    Nedlands, Western Australia 6009, Australia
  • Medizinische Universität Graz; Universitätsklinik für Neurologie
    Graz, 8036, Austria
  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie
    Innsbruck, 6020, Austria
  • Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie
    Salzburg, 5020, Austria
  • Medizinische Universität Wien; Univ.Klinik fuer Neurologie
    Wien, 1090, Austria
  • AZ Sint Jan
    Brugge, 8000, Belgium
  • UZ Brussel
    Brussel, 1090, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • CHU Tivoli
    La Louvière, 7100, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • Revalidatie en MS Centrum
    Overpelt, 3900, Belgium
  • Hospital das Clinicas - UFMG
    Belo Horizonte, MG 31270-901, Brazil
  • Instituto de Neurologia de Curitiba
    Curitiba, PR 81210-310, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Hospital das Clinicas - FMUSP
    Sao Paulo, SP 05403-010, Brazil
  • Shat Np Sveti Naum; 3Rd Clinic of Neurology
    Sofia, 1113, Bulgaria
  • Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
    Sofia, 1309, Bulgaria
  • UMHAT Alexandrovska, EAD; Neurology
    Sofia, 1431, Bulgaria
  • UBC Hospital; Div of Neurology, Dept of Medicine
    Vancouver, British Columbia V6T 1Z3, Canada
  • London Health Sciences Centre Uni Campus
    London, Ontario N6A 5A5, Canada
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1Y 4E9, Canada
  • Sunnybrook Health Science Centre
    Toronto, Ontario M4N 3M5, Canada
  • Clinique NeuroOutaouais
    Gatineau, Quebec J8Y 1W2, Canada
  • Recherche Sepmus Inc.
    Greenfield Park, Quebec J4V 2J2, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Aalborg Universitetshospital; Neurologisk Afdeling og Neurofysiologisk Afdeling; Skleroseamb.
    Aalborg, 9000, Denmark
  • Aarhus Universitetshospital; Neurologisk Afd. F, Skleroseklinikken
    Aarhus N, 8200, Denmark
  • Rigshospitalet; Neurologisk Klinik Glostrup
    Glostrup, 2600, Denmark
  • CHU de Besancon Hopital Jean Minjoz; Service de Neurologie
    Besançon, 25030, France
  • Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie
    Bordeaux, 33076, France
  • Hopital Pierre Wertheimer; Neurologie D
    Bron, 69677, France
  • CHU de Caen Hopital Cote de Nacre
    Caen, 14033, France
  • CHU Hopital Gabriel Montpied; Service de Neurologie
    Clermont Ferrand, 63003, France
  • CH de Gonesse; Neurologie
    Gonesse, 95503, France
  • CHU de Grenoble; Neurologie
    La Tronche, 38700, France
  • Hopital Gui de Chauliac; Neurologie
    Montpellier, 34295, France
  • Hopital Central - CHU de Nancy; Service de Neurologie
    Nancy, 54035, France
  • Hôpital Guillaume et René Laënnec; Service Neurologie
    Nantes, 44805, France
  • Hôpital Pasteur; Service de Neurologie
    Nice, 06002, France
  • CHU de Nîmes Hopital Caremeau; Service de Neurologie
    Nimes, 30900, France
  • Hôpital de Poissy; Service neurologie
    Poissy, 78300, France
  • Centre Hospitalier Universitaire de Rennes
    Rennes, 35033, France
  • CHU de Rouen Hopital; Service de Neurologie
    Rouen, 76031, France
  • CHU de Strasbourg
    Strasbourg, 67098, France
  • Hopital Foch; Neurologie
    Suresnes, 92151, France
  • HIA de Toulon hôpital militaire; Neurologie
    Toulon, 83041, France
  • CHU toulouse - Hôpital Purpan; Departement de Neurologie
    Toulouse, 31059, France
  • CHRU - Hôpital Bretonneau; Neurologie
    Tours, 37000, France
  • Praxis Dr.med. Sylvia Menck, Fachärztin für Neurologie und Psychiatrie
    Barsinghausen, 30890, Germany
  • Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie
    Berlin, 13347, Germany
  • St. Josef-Hospital, Klinik für Neurologie
    Bochum, 44791, Germany
  • Studienzentrum Dr. Bischof GmbH
    Böblingen, 71034, Germany
  • Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften
    Dresden, 01307, Germany
  • Universitätsklinikum Düsseldorf; Klinik für Neurologie
    Düsseldorf, 40225, Germany
  • NeuroCentrum Odenwald; Dres. Reifschneider, Unsorg, Ries, Schumann, Hoffmann, Knoblich
    Erbach/Odenwald, 64711, Germany
  • Universitätsklinikum Essen (AöR); Klinik für Neurologie
    Essen, 45147, Germany
  • MultipEL Studies - Institut für klinische Studien
    Hamburg, 22179, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Neurologische Gemeinschaftspraxis Kassel und Vellmar, Ch. Lassek, Dres. Ammerbach, Fetzer, M. Fische
    Kassel, 34121, Germany
  • Uniklinik Schleswig-Holstein; Neuroimmunologie, Institut für Klinische Chemie + Klinik f. Neurologie
    Kiel, 24105, Germany
  • Universitaetsklinikum Marburg; Klinik fuer Neurologie
    Marburg, 35043, Germany

Showing the first 100 of 193 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hartung HP; ENSEMBLE Steering Committee members and study investigators. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(5):e807. doi: 10.1212/NXI.0000000000000807. Print 2020 Sep. PubMed 32503093 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Apr 2023, 73 months.

Results were first posted in Jan 2025, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2017
First posted
Mar 21, 2017
StartActual
Mar 24, 2017
Primary completionActual
Apr 27, 2023
CompletionActual
Apr 27, 2023
Results first posted
Jan 15, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03085810
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 21, 2017
Start date
Mar 24, 2017
Primary completion
Apr 27, 2023
Completion
Apr 27, 2023
Results posted
Jan 15, 2025
Last update
Jan 15, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion